Oxime-functionalized anti-insecticide fabric reduces insecticide exposure through dermal and nasal routes, and prevents insecticide-induced neuromuscular-dysfunction and mortality
- PMID: 38844466
- PMCID: PMC11156901
- DOI: 10.1038/s41467-024-49167-3
Oxime-functionalized anti-insecticide fabric reduces insecticide exposure through dermal and nasal routes, and prevents insecticide-induced neuromuscular-dysfunction and mortality
Abstract
Farmers from South Asian countries spray insecticides without protective gear, which leads to insecticide exposure through dermal and nasal routes. Acetylcholinesterase plays a crucial role in controlling neuromuscular function. Organophosphate and carbamate insecticides inhibit acetylcholinesterase, which leads to severe neuronal/cognitive dysfunction, breathing disorders, loss of endurance, and death. To address this issue, an Oxime-fabric is developed by covalently attaching silyl-pralidoxime to the cellulose of the fabric. The Oxime-fabric, when stitched as a bodysuit and facemask, efficiently deactivates insecticides (organophosphates and carbamates) upon contact, preventing exposure. The Oxime-fabric prevents insecticide-induced neuronal damage, neuro-muscular dysfunction, and loss of endurance. Furthermore, we observe a 100% survival rate in rats when repeatedly exposed to organophosphate-insecticide through the Oxime-fabric, while no survival is seen when organophosphate-insecticide applied directly or through normal fabric. The Oxime-fabric is washable and reusable for at least 50 cycles, providing an affordable solution to prevent insecticide-induced toxicity and lethality among farmers.
© 2024. The Author(s).
Conflict of interest statement
P.K.V., K.T., and S.C. hold patents related to this technology: “Composition, materials, and methods for deactivating toxic agents” (Granted Indian patent: 201841006678 and granted Sri Lankan Patent # 20419). All compositions and methods of use described in this manuscript were covered in the patent applications. P.K.V., K.T., and S.C. are inventors of patents that were licensed to Sepio Health, a company that has licensed IP generated by P.K.V., K.T., and S.C., that may benefit financially if the IP is further validated. The interests of P.K.V. were reviewed and are subject to a management plan overseen by his institution in accordance with its conflict of interest policies. P.K.V. and O.S. are equity holders in Sepio Health. The remaining authors declare no competing interests.
Figures
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
